Ronald P. Taylor, PhD, University of Virginia

Ronald P. Taylor, PhD
Ronald P. Taylor, PhD

The Taylor laboratory studies new approaches for cancer treatment based on the interaction of cancer cells with the complement system. In the presence of serum and normal human IgM and/or specific monoclonal antibodies, large amounts of the complement activation product, C3bi, covalently bind to cancer cells. The lab uses monoclonal antibodies specific for cell-associated C3bi to facilitate tumor cell targeting and killing in their studies.

The Investigator's Annexe Part of The Investigator's Annexe program.

Products

References

  1. Taylor RP, Lindorfer MA. (2010) "Antigenic modulation and rituximab resistance." Semin Hematol. 47:124-32.
  2. Daubeuf S, Lindorfer MA, Taylor RP, Joly E, Hudrisier D. (2010) "The direction of plasma membrane exchange between lymphocytes and accessory cells by trogocytosis is influenced by the nature of the accessory cell." J Immunol. Feb 184:1897-908. Epub 2010 Jan 20.
  3. Aue G, Lindorfer MA, Beum PV, Pawluczkowycz AW, Vire B, Hughes T, Taylor RP,Wiestner A. (2010) "Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia." Haematologica. 95:329-32. Epub 2009 Aug 13.
  4. Pawluczkowycz AW, Beurskens FJ, Beum PV, Lindorfer MA, van de Winkel JG, ParrenPW, Taylor RP. (2009) "Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX." J Immunol. Jul 183:749-58. Epub 2009 Jun 17.
  5. Beum PV, Lindorfer MA, Taylor RP. (2008) "Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving." J Immunol. Aug 181:2916-24.
  6. Taylor RP, Lindorfer MA. (2008) "Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies." Curr Opin Immunol. 20:444-9. Epub 2008 Jul 1.
  7. Beum PV, Lindorfer MA, Beurskens F, Stukenberg PT, Lokhorst HM, PawluczkowyczAW, Parren PW, van de Winkel JG, Taylor RP. (2008) "Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis." J Immunol. Jul 181:822-32.
  8. Wang SY, Racila E, Taylor RP, Weiner GJ. (2008) "NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement." Blood. Feb 111:1456-63. Epub 2007 Nov 16.
  9. Lindorfer MA, Pawluczkowycz AW, Peek EM, Hickman K, Taylor RP, Parker CJ. A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement. Blood. 2010 Mar 18;115(11):2283-91.
  10. Beurskens FJ, Lindorfer MA, Farooqui M, Beum PV, Engelberts P, Mackus WJ, Parren PW, Wiestner A, Taylor RP. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients. J Immunol. 2012 Apr 1;188(7):3532-41.
  11. DiLillo DJ, Pawluczkowycz AW, Peng W, Kennedy AD, Beum PV, Lindorfer MA, Taylor RP. Selective and efficient inhibition of the alternative pathway of complement by a mAb that recognizes C3b/iC3b. Mol Immunol. 2006 Mar;43(7):1010-9.
  12. Kennedy AD, Solga MD, Schuman TA, Chi AW, Lindorfer MA, Sutherland WM, Foley PL, Taylor RP. An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab. Blood. 2003 Feb 1;101(3):1071-9.
    13. li>Ferguson PJ, Reist CJ, Martin EN, Johnson C, Greene KL, Kuhn S, Niebur J, Emlen W, Taylor RP. Antigen-based heteropolymers. A potential therapy for binding and clearing autoantibodies via erythrocyte CR1. Arthritis Rheum. 1995 Feb;38(2):190-200. PubMed PMID: 7848309.
  13. Hahn CS, French OG, Foley P, Martin EN, Taylor RP. Bispecific monoclonal antibodies mediate binding of dengue virus to erythrocytes in a monkey model of passive viremia. J Immunol. 2001 Jan 15;166(2):1057-65. PubMed PMID: 11145685.
  14. Craig ML, Waitumbi JN, Taylor RP. Processing of C3b-opsonized immune complexes bound to non-complement receptor 1 (CR1) sites on red cells: phagocytosis, transfer, and associations with CR1. J Immunol. 2005 Mar 1;174(5):3059-66. PubMed PMID: 15728520.